Use of an anti-Tau pS422 antibody for the treatment of brain diseases

Patent metadata

Field	Value
Publication number	US-9290567-B2
Application number	US-201313911991-A
Country	US
Kind code	B2
Filing date	Jun 6, 2013
Priority date	Jun 10, 2009
Publication date	Mar 22, 2016
Grant date	Mar 22, 2016

Abstract

An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

First claim

The invention claimed is:

1. An antibody, which specifically binds to Tau phosphorylated at serine 442 (Tau pS422) and to the phosphorylated Tau fragment of SEQ ID NO:9 but does not bind to either wild-type Tau or to the phosphorylated human mitotic centromere-associated kinesin (MCAK) fragment of SEQ ID NO:17, and which comprises the complementary determining regions (CDRs): CDR1H of SEQ ID NO:55, CDR2H of SEQ ID NO:56, CDR3H of SEQ ID NO:57, CDR1L of SEQ ID NO:59, CDR2L of SEQ ID NO:60, and CDR3L of SEQ ID NO:61, wherein the antibody is a variant antibody that has been humanized.

2. An antibody, which specially binds to Tau pS422 and to the phosphorylated Tau fragment of SEQ ID NO:9 but does not bind to either wild-type Tau or to the phosphorylated MCAK fragment of SEQ ID NO:17, and which comprises a variable light chain of SEQ ID NO:58 and a variable heavy chain of SEQ ID NO:54, wherein the antibody is a variant antibody that has been humanized.

Assignees

• Hoffmann La Roche

Inventors

• Bohrmann Bernd
• Goepfert Ulrich
• Grueninger Fiona
• Huber Walter
• Krell Hans-Willi
• Lifke Valeria
• Mundigl Olaf
• Offner Sonja
• Ozmen Laurence
• Schraemi Michael

Classifications

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K2319/55

  containing a fusion with a toxin, e.g. diphteria toxin · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title